Amitiza and Thyroiditis - a phase IV clinical study of FDA data

Summary:

Thyroiditis is reported as a side effect among people who take Amitiza (lubiprostone), especially for people who are female, 60+ old, also take Opdivo, and have Metastatic renal cell carcinoma.

The phase IV clinical study analyzes which people have Thyroiditis when taking Amitiza. It is created by eHealthMe based on reports of 10,225 people who have side effects when taking Amitiza from the FDA, and is updated regularly.

What is Amitiza?

Amitiza has active ingredients of lubiprostone. It is often used in constipation. eHealthMe is studying from 10,567 Amitiza users. Check the latest studies of Amitiza.

What is Thyroiditis?

Thyroiditis (inflammation of thyroid gland) is found to be associated with 362 drugs and 386 conditions by eHealthMe. Check the latest studies of Thyroiditis.

On Sep, 26, 2025

10,225 people reported to have side effects when taking Amitiza.
Among them, 14 people (0.14%) have Thyroiditis.

Among these 14 people:

What is the gender of people who have Thyroiditis when taking Amitiza? *

female: 78.57 %
male: 21.43 %

What is the age of people who have Thyroiditis when taking Amitiza? *

What are other drugs people take besides Amitiza? *

What are other side effects people have besides Thyroiditis? *

Eosinophil Count Increased: 4 people, 28.57%
Malignant Neoplasm Progression (cancer tumour came back): 4 people, 28.57%
Diarrhea: 4 people, 28.57%
High Blood Pressure: 3 people, 21.43%
Fall: 2 people, 14.29%
Hyponatremia (abnormally low level of sodium in the blood; associated with dehydration): 2 people, 14.29%
Weakness: 2 people, 14.29%
Hyperthyroidism (over activity of the thyroid gland): 2 people, 14.29%
Fibromyalgia (a long-term condition which causes pain all over the body): 2 people, 14.29%
Feeling Abnormal: 2 people, 14.29%

What are the existing conditions these people have? *

Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 4 people, 28.57%
Renal Cell Carcinoma Stage Iv (stage iv renal cell cancer have cancer that has spread to other organs, such as the lungs, liver, bones, or brain, and may have spread to lymph nodes): 2 people, 14.29%
Cholangiocarcinoma (a cancer that forms glands or secretes significant amounts of mucins): 2 people, 14.29%
Cholangitis (infection of the bile duct): 2 people, 14.29%
Dermatitis Allergic (inflammation of the skin due allergic reaction): 2 people, 14.29%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 14.29%
Hepatitis Cholestatic (flow of bile from the liver is slowed or blocked): 2 people, 14.29%
Cardiac Failure Chronic: 2 people, 14.29%
Nausea And Vomiting: 2 people, 14.29%
Renal Cell Carcinoma (a kidney cancer): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Amitiza and have Thyroiditis?

- Check whether Thyroiditis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Amitiza:

Amitiza (10,567 reports)

Thyroiditis treatments and more:

Thyroiditis (4,154 reports)

How severe was Thyroiditis and when was it recovered:

Thyroiditis in Amitiza

Browse all side effects of Amitiza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Thyroiditis:

Thyroiditis (362 drugs)

Browse all the conditions that are associated with Thyroiditis:

Thyroiditis (386 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lubiprostone (the active ingredients of Amitiza) and Amitiza (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.